Leica Biosystems Nussloch GmbH

Company Overview

Leica Biosystems joined Danaher Corp. in 2006. It is a cancer diagnostics company offering a comprehensive portfolio that spans the entire workflow from biopsy to diagnosis. The company provides a wide product range for each step in the pathology process, from sample preparation and staining to imaging and reporting.

Leica Biosystems is headquartered in Germany and operates in over 100 countries. Products from Leica Biosystems focus on addressing multiplexing needs for researchers to assess multiple biomarkers (protein and/or nucleic acid markers) at specific locations within a tissue sample. The products of Leica Biosystems are categorized as histology equipment, histology consumables, immunohistochemistry (IHC), in situ hybridization (ISH), fluorescent in situ hybridization (FISH) and digital pathology. It also provides clinical solutions and life science research solutions.

Some established products of the company are Histocore Peloris 3, Histocore PEARL, Histocore Biocut, fully automated IHC and ISH instruments, Agile Stainer BOND-MAX, IHC primary antibodies for different diseases, detection systems, Aperio GT 450, Aperio GT 450 DX, Aperio CS2 and Aperio VERSA.

Leica Biosystems is also involved in providing companion diagnostics (CDx) solutions for customers. The Leica HER2 FISH System for BOND combines PathVysion LSI HER2/CEP17 FISH probes and advanced BOND automation. The Bond Oracle HER2 IHC System is an FDA-approved diagnostic tool for breast cancer. The Bond Oracle HER2 IHC System is a fully automated assay to determine HER2 oncoprotein status in breast cancer tissue and is used as a support during the assessment of patients receiving Herceptin (trastuzumab) treatment.

Company's Business Segments

• Products : Histology Solutions, IHC and ISH, Digital Pathology, Research Solutions
• Life Science : Histology and Pre-Analytics, IHC and Multiplexing, Digital Pathology Imaging and Scanning, Innovation Partners and Technology, Cell Idx.